• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    8/19/22 5:56:39 PM ET
    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADGI alert in real time by email

    Gainers

    • Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 83.1% to $0.69 during Friday's after-market session. Trading volume for this security closed at 5.8 million, accounting for 454.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.9 million.
    • Summit Therapeutics (NASDAQ:SMMT) stock moved upwards by 26.36% to $1.39. At the close, Summit Therapeutics's trading volume reached 4.2 million shares. This is 2054.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $279.3 million.
    • Ontrak (NASDAQ:OTRKP) stock rose 17.61% to $2.47.
    • Adagio Therapeutics (NASDAQ:ADGI) shares rose 8.09% to $4.54. This security traded at a volume of 61.3K shares come close, making up 7.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $494.0 million. As per the news, the Q2 earnings report came out 4 days ago.
    • AnPac Bio-Medical Science (NASDAQ:ANPC) shares rose 7.22% to $0.23. The market value of their outstanding shares is at $9.0 million.
    • Neuronetics (NASDAQ:STIM) stock rose 7.21% to $4.46. The market value of their outstanding shares is at $120.5 million.

    Losers

    • Amarin Corp (NASDAQ:AMRN) shares fell 7.6% to $1.46 during Friday's after-market session. This security traded at a volume of 103.4K shares come close, making up 2.8% of its average volume over the last 100 days. The company's market cap stands at $588.6 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares fell 7.58% to $0.84. Today's trading volume for this security ended up closing at 10.4 million shares, which is 1199.4 percent of its average volume over the last 100 days. The company's market cap stands at $51.4 million.
    • Endo International (NASDAQ:ENDP) shares fell 7.43% to $0.37. This security traded at a volume of 23.8 million shares come close, making up 41.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $87.0 million.
    • Solid Biosciences (NASDAQ:SLDB) stock fell 6.14% to $0.79. The market value of their outstanding shares is at $89.0 million.
    • Genprex (NASDAQ:GNPX) stock declined by 5.51% to $1.89. The market value of their outstanding shares is at $90.7 million.
    • Exscientia (NASDAQ:EXAI) stock decreased by 4.96% to $9.78. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q2 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGI
    $AGLE
    $AMRN
    $ANPC

    CompanyDatePrice TargetRatingAnalyst
    Solid Biosciences Inc.
    $SLDB
    3/20/2026$26.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    More analyst ratings

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Solid Biosciences with a new price target

    Guggenheim initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $26.00

    3/20/26 8:37:32 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Summit Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00

    3/16/26 8:36:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chernett Jorey

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/27/26 9:33:23 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Pfanstiel Steven

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/24/26 5:52:12 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Sullivan Keith J

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/24/26 5:50:30 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    SEC Filings

    View All

    Amarin Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

    3/27/26 5:00:07 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Solid Biosciences Inc.

    S-3 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 5:04:40 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Solid Biosciences Inc.

    S-3 - Solid Biosciences Inc. (0001707502) (Filer)

    3/19/26 5:03:02 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xia Yu bought $9,999,983 worth of shares (533,617 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 9:06:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $499,983 worth of shares (26,680 units at $18.74) and was granted 14,247,597 shares, increasing direct ownership by 3% to 570,073,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:08:30 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Zanganeh Mahkam was granted 14,247,597 shares and bought $499,983 worth of shares (26,680 units at $18.74) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    10/23/25 4:06:32 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

    Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress (ELCC 2026) in Copenhagen, Denmark. Three posters featuring updated ivonescimab data will be displayed on Friday, March 27 from 1:00 to 2:00 pm Central European Time. Data for HARMONi was generated and analyzed by Summit and for HARMONi-2 by our collaboration and licensing partner, Akeso Inc. (HKE

    3/27/26 8:15:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    - Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 - - Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 - - Friedreich's Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events - - CPVT (SGT-501): Clinical s

    3/19/26 4:12:05 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

    DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with hypertriglyceridemia be part of a broader dyslipidemia management as discussed in the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update.i  These newly-issued, evidenced-based recommendations summarize the clinical role of icosapent ethyl (IPE) in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides (TG) and full

    3/18/26 8:30:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Neuronetics Appoints New Chief Financial Officer

    Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company's new Chief Financial

    7/15/25 7:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $AGLE
    $AMRN
    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exscientia Plc

    SC 13G/A - Exscientia plc (0001865408) (Subject)

    11/22/24 9:11:55 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Exscientia Plc

    SC 13D/A - Exscientia plc (0001865408) (Subject)

    11/22/24 8:00:16 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care